138 related articles for article (PubMed ID: 21916856)
21. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study.
Sarkar AK; Tortolero-Luna G; Follen M; Sastry KJ
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S251-61. PubMed ID: 16188303
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
23. The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix.
Song SH; Lee JK; Seok OS; Saw HS
Gynecol Oncol; 2007 Mar; 104(3):732-8. PubMed ID: 17188341
[TBL] [Abstract][Full Text] [Related]
24. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96.
Wadler S; Levy D; Frederickson HL; Falkson CI; Wang Y; Weller E; Burk R; Ho G; Kadish AS;
Gynecol Oncol; 2004 Mar; 92(3):957-64. PubMed ID: 14984966
[TBL] [Abstract][Full Text] [Related]
26. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
Shahbazi S; Bolhassani A
Int Immunopharmacol; 2018 Sep; 62():170-180. PubMed ID: 30015237
[TBL] [Abstract][Full Text] [Related]
27. HPV: from infection to cancer.
Stanley MA; Pett MR; Coleman N
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1456-60. PubMed ID: 18031245
[TBL] [Abstract][Full Text] [Related]
28. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
[TBL] [Abstract][Full Text] [Related]
29. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells.
Komatsu A; Igimi S; Kawana K
Vaccine; 2018 Jun; 36(24):3423-3426. PubMed ID: 29735324
[TBL] [Abstract][Full Text] [Related]
30. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
Paaso A; Koskimaa HM; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
J Transl Med; 2015 May; 13():163. PubMed ID: 25990808
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus vaccines for the treatment of cervical cancer.
Sin JI
Expert Rev Vaccines; 2006 Dec; 5(6):783-92. PubMed ID: 17184217
[TBL] [Abstract][Full Text] [Related]
32. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
Gomez-Gutierrez JG; Elpek KG; Montes de Oca-Luna R; Shirwan H; Sam Zhou H; McMasters KM
Cancer Immunol Immunother; 2007 Jul; 56(7):997-1007. PubMed ID: 17146630
[TBL] [Abstract][Full Text] [Related]
33. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
34. Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy.
Delgado FG; Martínez E; Céspedes MA; Bravo MM; Navas MC; Cómbita Rojas AL
Immunology; 2009 Apr; 126(4):523-34. PubMed ID: 18778290
[TBL] [Abstract][Full Text] [Related]
35. Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.
Salehi M; Taheri T; Mohit E; Zahedifard F; Seyed N; Taslimi Y; Sattari M; Bolhassani A; Rafati S
Immunotherapy; 2012 Nov; 4(11):1107-20. PubMed ID: 23194361
[TBL] [Abstract][Full Text] [Related]
36. Antibody response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with cervical cancer.
Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maâlej M; Oueslati R
J Immunoassay Immunochem; 2009; 30(1):82-96. PubMed ID: 19117204
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression.
Marquez JP; Rivera R; Kang KH; Gardner MB; Torres JV
Viral Immunol; 2012 Apr; 25(2):141-52. PubMed ID: 22486305
[TBL] [Abstract][Full Text] [Related]
38. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
[TBL] [Abstract][Full Text] [Related]
39. Characterization and evaluation of the immune responses elicited by a novel human papillomavirus (HPV) therapeutic vaccine: HPV 16E7-HBcAg-Hsp65 fusion protein.
Zhou CM; Zhang GX; Ma XX
J Virol Methods; 2014 Mar; 197():1-6. PubMed ID: 24291739
[TBL] [Abstract][Full Text] [Related]
40. Vaccination Against Human Papilloma Viruses Leads to a Favorable Cytokine Profile of Specific T Cells.
Luckau S; Wehrs TP; Brandau S; Horn PA; Lindemann M
J Immunother; 2016 Oct; 39(8):316-20. PubMed ID: 27548034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
